Aetna ACA Plans: Higher Prices Drove Exit | STAT News
The health insurance landscape continues to shift, with recent developments highlighting the financial pressures within the Affordable Care Act (ACA) marketplaces and ongoing consolidation among major players. Aetna, a subsidiary of CVS Health, exited ACA plans earlier this year, citing unsustainable medical claims. Now, new data reveals insights into the pricing dynamics Aetna faced, alongside news of a deal involving Cigna.
Aetna’s ACA Pricing Challenges
Aetna stopped selling Affordable Care Act plans in 2026, a decision the company attributed to a high volume of medical claims among its ACA members. CEO David Joyner previously stated there was “not a near- or long-term pathway for Aetna to materially improve its position in this product.” Recent analysis, as reported by STAT+, sheds light on a key factor: Aetna consistently paid higher prices for hospital care within its ACA plans compared to other insurers. STAT+’s reporting indicates that Aetna’s rates for hospital services were significantly above the median, potentially contributing to the financial strain that led to its exit from the ACA market.
This finding is particularly relevant as the ACA marketplaces aim to provide affordable coverage options. Higher hospital prices directly translate to increased premiums for consumers. The data underscores the complex interplay between insurer negotiating power, hospital pricing strategies, and the overall cost of healthcare. It too raises questions about the sustainability of ACA plans if insurers are unable to secure competitive rates from hospitals. Understanding these dynamics is crucial for policymakers seeking to stabilize the marketplaces and ensure access to affordable care.
Cigna’s Acquisition of CarepathRx
In a separate development, Cigna announced its acquisition of CarepathRx, a pharmacy benefit manager (PBM) focused on specialty medications. STAT+ reports this move strengthens Cigna’s position in the PBM space and expands its capabilities in managing complex and costly drug therapies. Specialty medications, used to treat conditions like cancer, rheumatoid arthritis, and multiple sclerosis, represent a growing portion of overall pharmaceutical spending.
PBMs play a critical role in negotiating drug prices with manufacturers, creating formularies (lists of covered drugs), and processing prescription claims. By acquiring CarepathRx, Cigna aims to enhance its ability to control costs and improve outcomes for patients requiring specialty medications. This acquisition is part of a broader trend of consolidation within the PBM industry, as companies seek to gain scale and leverage their negotiating power. The impact of this consolidation on drug prices and patient access remains a subject of ongoing debate.
What are Pharmacy Benefit Managers?
Pharmacy benefit managers (PBMs) act as intermediaries between health plans, pharmacies, and drug manufacturers. They negotiate discounts and rebates with drug companies, develop formularies, and process prescription claims. PBMs aim to lower drug costs for health plans and their members, but their practices have come under scrutiny in recent years. Concerns have been raised about a lack of transparency in PBM pricing and potential conflicts of interest. The Centers for Medicare & Medicaid Services (CMS) provides further information on PBMs and their role in the healthcare system.
Implications for Consumers and the Healthcare System
Aetna’s exit from the ACA marketplaces and Cigna’s acquisition of CarepathRx are indicative of broader trends reshaping the healthcare industry. Aetna’s experience highlights the challenges insurers face in managing costs within the ACA, particularly related to hospital pricing. The Cigna deal underscores the ongoing consolidation within the PBM sector and the increasing focus on managing specialty drug costs.
For consumers, these developments could translate to fewer insurance options in some markets and potentially higher premiums. The consolidation of PBMs could also impact drug prices and access to certain medications. It’s significant to note that the effects of these changes will vary depending on individual circumstances and geographic location.
Hospital Pricing and Market Power
The issue of hospital pricing is a complex one, often tied to market power. In areas where a few large hospital systems dominate the market, they may have greater leverage to negotiate higher rates with insurers. This can drive up healthcare costs for everyone. Efforts to promote price transparency and competition among hospitals are ongoing, but progress has been slow. The Federal Trade Commission (FTC) is actively investigating hospital mergers and acquisitions to ensure they do not harm competition. The FTC’s recent request for public comment on hospital consolidation signals a heightened focus on this issue.
What Comes Next: Regulatory Scrutiny and Market Adjustments
The healthcare industry is facing increased regulatory scrutiny, particularly regarding hospital pricing and PBM practices. Federal agencies, such as the FTC and CMS, are actively investigating potential anti-competitive behavior and seeking to promote transparency. The Biden administration has also proposed rules to lower drug prices and increase access to affordable care.
In the coming months, One can expect to see further market adjustments as insurers and PBMs respond to these regulatory pressures and competitive dynamics. The ACA marketplaces will continue to evolve, with potential changes in insurer participation and premium levels. Consumers should stay informed about their options and advocate for policies that promote affordable and accessible healthcare. Monitoring developments from CMS and the FTC will be crucial for understanding the evolving landscape.